- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01157377
Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence
February 4, 2014 updated by: Allergan
This study will evaluate the safety and efficacy of AGN-214868 in patients with idiopathic overactive bladder (IOAB) and urinary incontinence.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
160
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Lyon, France
-
-
-
-
-
Amsterdam, Netherlands
-
-
-
-
Virginia
-
Richmond, Virginia, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- If female, must be of nonreproductive potential
- If male, must agree to use acceptable contraception
- Symptoms of overactive bladder with urinary urgency incontinence
- Inadequate response or limiting side effects with anticholinergics for the treatment of OAB
Exclusion Criteria:
- Overactive bladder caused by neurological condition (eg, spinal cord injury, multiple sclerosis)
- History of bladder surgery
- Treatment with botulinum toxin therapy of any serotype for any non-urological condition within the prior 12 weeks
- Previous treatment with botulinum toxin therapy of any serotype for any urological condition
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AGN-214868 total dose 500 ng
AGN-214868 injected into the bladder for total dose of 500 ng on Day 1.
|
AGN-214868 injected into the bladder.
|
Experimental: AGN-214868 total dose 1000 ng
AGN-214868 injected into the bladder for total dose of 1000 ng on Day 1.
|
AGN-214868 injected into the bladder.
|
Experimental: AGN-214868 total dose 2000 ng
AGN-214868 injected into the bladder for total dose of 2000 ng on Day 1.
|
AGN-214868 injected into the bladder.
|
Experimental: AGN-214868 total dose 6000 ng
AGN-214868 injected into the bladder for total dose of 6000 ng on Day 1.
|
AGN-214868 injected into the bladder.
|
Experimental: AGN-214868 total dose 18000 ng
AGN-214868 injected into the bladder for total dose of 18000 ng on Day 1.
|
AGN-214868 injected into the bladder.
|
Experimental: AGN-214868 total dose 60000 ng
AGN-214868 injected into the bladder for total dose of 60000 ng on Day 1.
|
AGN-214868 injected into the bladder.
|
Placebo Comparator: Placebo to AGN-214868
Placebo to AGN-214868 injected into the bladder on Day 1.
|
AGN-214868 placebo injected into the bladder.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in the Daily Average Number of Micturition (Urination) Episodes
Time Frame: Baseline, Week 12
|
The average number of urinary episodes (urination into the toilet) was recorded by a patient bladder diary during 3 consecutive days in the week prior to Baseline and Week 12.
A negative change from Baseline indicated improvement (fewer urinary episodes).
|
Baseline, Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2010
Primary Completion (Actual)
February 1, 2013
Study Completion (Actual)
May 1, 2013
Study Registration Dates
First Submitted
July 1, 2010
First Submitted That Met QC Criteria
July 2, 2010
First Posted (Estimate)
July 7, 2010
Study Record Updates
Last Update Posted (Estimate)
March 19, 2014
Last Update Submitted That Met QC Criteria
February 4, 2014
Last Verified
February 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 214868-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Bladder, Overactive
-
Merck Sharp & Dohme LLCTerminatedOveractive Bladder | Overactive Urinary Bladder
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder SyndromeTurkey
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
Medstar Health Research InstituteColumbia University; University of Michigan; University of New Mexico; Methodist...Terminated
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Loyola UniversityAstellas Pharma IncCompletedOveractive Bladder SyndromeUnited States
-
Beijing Pins Medical Co., LtdUnknown
-
Maastricht University Medical CenterUnknownLower Urinary Tract Symptoms | Overactive Bladder SyndromeNetherlands
-
Pamukkale UniversityCompletedElectrical Stimulation | Idiopathic Overactive Bladder | Bladder TrainingTurkey
Clinical Trials on AGN-214868
-
AllerganTerminatedNeuralgia, PostherpeticUnited States, Austria, Poland, Germany
-
AllerganCompletedNeuralgia, PostherpeticPoland, United States, Czech Republic, Germany
-
AllerganCompleted
-
AllerganCompletedHealthy VolunteersUnited States
-
AllerganCompletedMeibomian Gland DysfunctionUnited States
-
AllerganCompletedErythema | RosaceaUnited States
-
AllerganCompletedPresbyopiaUnited States
-
AllerganCompletedErythema | RosaceaUnited States
-
AllerganCompleted
-
AllerganCompletedPresbyopiaUnited States